Increasing Dose of Autologous Bone Marrow Mononuclear Cells Transplantation Is Related to Stroke Outcome: Results from a Pooled Analysis of Two Clinical Trials

Table 3

Published clinical trials with BM-MNC therapy in stroke patients.

Author	Cell population	Number of patients; treated (controls)	Design	Route	Cell dose	Time window	Follow-up (months)	Adverse events
Suárez-Monteagudo et al. [14]	Autologous	5 (0)	Open-label phase I	Intraparenchymal		1–10 years	12	Headache, drowsiness, nausea, fever
Savitz et al. [11]	Autologous	10 (0)	Open-label phase I	Intravenous		24–72 hours	6	None study-related reported
Friedrich et al. [15]	Autologous	20 (0)	Open-label phase I	Intra-arterial		3–7 days	6	None study-related reported
Moniche et al. [7]	Autologous	10 (10)	Observer-blinded phase I/II	Intra-arterial		5–9 days	6	Seizures (2 of 10)
Prasad et al. [16]	Autologous	11 (0)	Open-label phase I	Intravenous		7–30 days	6	One reinfarction
Li et al. [17]	Autologous	60 (40)	Observer-blinded phase I/II (hemorrhagic stroke)	Intraparenchymal		5–7 days	6	Fever, one unspecified pulmonary tumor
Barbosa da Fonseca et al. [18], Battistella et al. [8], Rosado-de-Castro et al. [9]	Autologous	12 (0)	Open-label phase I	Intravenous (), intra-arterial ()		19–89 days	6	Seizures (7 of 12)
Prasad et al. [10]	Autologous	85 (35)	Blinded randomized phase II	Intravenous		18.5 days	12	None reported
Sharma et al. [19]	Autologous	24 (0)	Open-label phase I/II (ischemic and hemorrhagic stroke)	Intrathecal		40 months	30	None reported
Taguchi et al. [20]	Autologous	12 (0)	Open-label phase I/II	Intravenous		7–10 days	6	One recurrent stroke